WO2004012765A1 - Preparation medicinale et procede de traitement d'un syndrome pathologique determine par une perturbation de l'hematopoiese - Google Patents
Preparation medicinale et procede de traitement d'un syndrome pathologique determine par une perturbation de l'hematopoiese Download PDFInfo
- Publication number
- WO2004012765A1 WO2004012765A1 PCT/RU2002/000366 RU0200366W WO2004012765A1 WO 2004012765 A1 WO2004012765 A1 WO 2004012765A1 RU 0200366 W RU0200366 W RU 0200366W WO 2004012765 A1 WO2004012765 A1 WO 2004012765A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antibodies
- anτiτel
- πuτem
- erythropoietin
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Definitions
- Izves ⁇ en s ⁇ s ⁇ b treatment ⁇ a ⁇ l ⁇ giches ⁇ g ⁇ Sind ⁇ ma, svyazann ⁇ g ⁇ with na ⁇ usheniem ⁇ ve ⁇ v ⁇ eniya, ⁇ u ⁇ em administration ⁇ ganizm ⁇ e ⁇ mbinan ⁇ n ⁇ g ⁇ chel ⁇ veches ⁇ g ⁇ e ⁇ i ⁇ e ⁇ ina (see., Na ⁇ ime ⁇ , ⁇ egis ⁇ le ⁇ a ⁇ s ⁇ venny ⁇ s ⁇ eds ⁇ v ⁇ ssii "Entsi ⁇ l ⁇ ediya le ⁇ a ⁇ s ⁇ v" edition 7, ⁇ s ⁇ va, ⁇ LS, 2000, s.789).
- human or heterologous eritrogen alpha, beta or omega are used, including recombinant or genetically engineered.
- the predominant use of the mixture is various, preferably commercially available, homogenous dilutions.
- the medicinal product is prepared by the following process.
- the resulting immune antibodies cleans by the method of affinity chromatography with protein ⁇ .
- the current processing in the process of reducing the concentration is also possible to carry out ultrasound, electric or other physical interference.
- mice line S ⁇ / Saas ⁇ n ⁇ ln ⁇ y and ⁇ y ⁇ n ⁇ y g ⁇ u ⁇ ⁇ edva ⁇ i ⁇ eln ⁇ vv ⁇ dili ad ⁇ iamitsin in d ⁇ ze 6 mg / ⁇ g ⁇ dn ⁇ a ⁇ n ⁇ vnu ⁇ ib ⁇ yushinn ⁇ .
- the lively commercial group received an appropriate consumer (distilled water) in an equivalent volume for the same purpose.
- C 3 ⁇ 10th and 12th su ⁇ i e ⁇ s ⁇ e ⁇ imen ⁇ a zhiv ⁇ ny ⁇ ume ⁇ schvlyali me ⁇ d ⁇ m tse ⁇ vi ⁇ aln ⁇ y disl ⁇ atsii ⁇ zv ⁇ n ⁇ chni ⁇ a, ⁇ edelyali ⁇ bschuyu ⁇ le ⁇ chn ⁇ s ⁇ ⁇ s ⁇ n ⁇ g ⁇ m ⁇ zga ( ⁇ ), ⁇ bschee ⁇ liches ⁇ v ⁇ ley ⁇ tsi ⁇ v ( ⁇ L) ⁇ e ⁇ i ⁇ ul ⁇ tsi ⁇ v and e ⁇ i ⁇ tsi ⁇ v in ⁇ e ⁇ i ⁇ e ⁇ iches ⁇ y ⁇ vi.
- the corresponding myeloma and the hematogram were calculated.
- SIGNIFICANT FOX (DR. 26) Table 1.
- mice * ** ***. The differences in intact mice are available; $, $$ differences are available, respectively, ⁇ ⁇ 0.05; 0.01; 0.001
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2002325432A AU2002325432A1 (en) | 2002-08-02 | 2002-08-02 | Medicinal agent and method for curing pathological syndrome associated to hemodiscrasia |
PCT/RU2002/000366 WO2004012765A1 (fr) | 2002-08-02 | 2002-08-02 | Preparation medicinale et procede de traitement d'un syndrome pathologique determine par une perturbation de l'hematopoiese |
IL16627005A IL166270A0 (en) | 2002-08-02 | 2005-01-06 | A pharmaceutical composition containing an activated form of ultra small doses of antibodies to the endothelial nitric acid synthase |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/RU2002/000366 WO2004012765A1 (fr) | 2002-08-02 | 2002-08-02 | Preparation medicinale et procede de traitement d'un syndrome pathologique determine par une perturbation de l'hematopoiese |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004012765A1 true WO2004012765A1 (fr) | 2004-02-12 |
Family
ID=31492974
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/RU2002/000366 WO2004012765A1 (fr) | 2002-08-02 | 2002-08-02 | Preparation medicinale et procede de traitement d'un syndrome pathologique determine par une perturbation de l'hematopoiese |
Country Status (3)
Country | Link |
---|---|
AU (1) | AU2002325432A1 (fr) |
IL (1) | IL166270A0 (fr) |
WO (1) | WO2004012765A1 (fr) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7700096B2 (en) | 2002-08-02 | 2010-04-20 | Oleg Iliich Epshtein | Medicinal agent for treating erectile dysfunction |
US8535664B2 (en) | 2000-06-20 | 2013-09-17 | Oleg I. Epshtein | Method of treating a pathological syndrome and a pharmaceutical agent |
US9308259B2 (en) | 2006-06-06 | 2016-04-12 | Oleg Iliich Epshtein | Medicinal agent for treating fatness, diabetes, and diseases associated with impaired glucose tolerance |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2070338C1 (ru) * | 1992-03-03 | 1996-12-10 | Сергей Владимирович Панько | Способ пересадки костного мозга в область кости в эксперименте |
RU95119854A (ru) * | 1993-03-31 | 1998-01-10 | Про-Ньюрон, Инк. | Ингибитор пролиферации стволовых клеток и его использование |
US5885574A (en) * | 1994-07-26 | 1999-03-23 | Amgen Inc. | Antibodies which activate an erythropoietin receptor |
WO2001097842A1 (fr) * | 2000-06-20 | 2001-12-27 | Oleg Iliich Epshtein | Procede de traitement d'un syndrome pathologique et produit medicamenteux |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1089344C (zh) * | 1993-03-31 | 2002-08-21 | 普罗神经细胞有限公司 | 干细胞增生的抑制剂及其应用 |
-
2002
- 2002-08-02 WO PCT/RU2002/000366 patent/WO2004012765A1/fr not_active Application Discontinuation
- 2002-08-02 AU AU2002325432A patent/AU2002325432A1/en not_active Abandoned
-
2005
- 2005-01-06 IL IL16627005A patent/IL166270A0/xx unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2070338C1 (ru) * | 1992-03-03 | 1996-12-10 | Сергей Владимирович Панько | Способ пересадки костного мозга в область кости в эксперименте |
RU95119854A (ru) * | 1993-03-31 | 1998-01-10 | Про-Ньюрон, Инк. | Ингибитор пролиферации стволовых клеток и его использование |
US5885574A (en) * | 1994-07-26 | 1999-03-23 | Amgen Inc. | Antibodies which activate an erythropoietin receptor |
WO2001097842A1 (fr) * | 2000-06-20 | 2001-12-27 | Oleg Iliich Epshtein | Procede de traitement d'un syndrome pathologique et produit medicamenteux |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8535664B2 (en) | 2000-06-20 | 2013-09-17 | Oleg I. Epshtein | Method of treating a pathological syndrome and a pharmaceutical agent |
US8871203B2 (en) | 2000-06-20 | 2014-10-28 | Oleg I. Epshtein | Method of treating a pathological syndrome and a pharmaceutical agent |
US8894995B2 (en) | 2000-06-20 | 2014-11-25 | Oleg Iliich Epshtein | Method of treating a disorder or condition of viral etiology |
US9200081B2 (en) | 2000-06-20 | 2015-12-01 | Oleg Iliich Epshtein | Method for administering homeopathically potentiated antibodies against mediator of inflammation |
US9228024B2 (en) | 2000-06-20 | 2016-01-05 | Oleg Iliich Epshtein | Method of treating hypertension disorder and a pharmaceutical agent |
US9303091B2 (en) | 2000-06-20 | 2016-04-05 | Oleg Iliich Epshtein | Method of treating disorders of the cardiovascular system and a pharmaceutical agent |
US9303090B2 (en) | 2000-06-20 | 2016-04-05 | Oleg Iliich Epshtein | Method of treating a pathological syndrome and a pharmaceutical agent |
US9382332B2 (en) | 2000-06-20 | 2016-07-05 | Oleg Iliich Epshtein | Method of treating a pathological syndrome and a pharmaceutical agent |
US7700096B2 (en) | 2002-08-02 | 2010-04-20 | Oleg Iliich Epshtein | Medicinal agent for treating erectile dysfunction |
US9308259B2 (en) | 2006-06-06 | 2016-04-12 | Oleg Iliich Epshtein | Medicinal agent for treating fatness, diabetes, and diseases associated with impaired glucose tolerance |
Also Published As
Publication number | Publication date |
---|---|
IL166270A0 (en) | 2006-01-15 |
AU2002325432A1 (en) | 2004-02-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2003055519A1 (fr) | Agent pharmaceutique et methode de traitement de maladies s'accompagnant de troubles du tonus vasculaire | |
WO2005000350A1 (fr) | Medicament et methode de traitement d'un syndrome pathologique | |
WO2004012764A1 (fr) | Medicament et procede de traitement des maladies de la prostate | |
AU2011287292B2 (en) | Combination pharmaceutical composition and methods of treating and preventing the infectious diseases | |
US20010018053A1 (en) | Methods for treating disease states comprising administration of low levels of antibodies | |
JPH09509411A (ja) | 上昇したインターロイキン−6血清レベルを有する疾病を治療するための医薬としてのアンチ−tnf抗体の使用 | |
EA029400B1 (ru) | Фармацевтическая композиция для лечения ожирения и сопутствующих метаболических расстройств и способ лечения | |
WO2004012767A1 (fr) | Preparation medicinale et procede de traitement de dyserections | |
KR20130060264A (ko) | 위장관의 기능적 질환 또는 이상을 치료하는 제약학적 복합 조성물 및 방법들 | |
CN103097414A (zh) | 膜联蛋白1抗体 | |
WO2004012766A1 (fr) | Procede de correction de reactions immunitaires pathologiques et preparation medicinale | |
CA2473754C (fr) | Traitement | |
WO2005039636A1 (fr) | Produit pour potentialiser les effets curatifs et intensifier l'action d'un medicament | |
WO2005007187A1 (fr) | Methode de traitement des maladies oncologiques, infectieuses et somatiques, procedes de controle de l'efficacite du traitement, agents et compositions pharmaceutiques associes | |
WO2003055518A1 (fr) | Procede de traitement d'etats immuno-pathologiques et medicament correspondant | |
WO2004012765A1 (fr) | Preparation medicinale et procede de traitement d'un syndrome pathologique determine par une perturbation de l'hematopoiese | |
RU2192882C1 (ru) | Лекарственное средство и способ лечения патологического синдрома, обусловленного нарушением кроветворения | |
US7589062B2 (en) | Two synthetic peptides for treatment and prevention of cancers | |
WO2003077946A1 (fr) | Agent pharmaceutique et methode de traitement d'un syndrome pathologique associe a hemodyscrasia | |
WO2003037372A1 (fr) | Procede de retablissement de processus physiologiques perturbes et medicament | |
WO2005004789A2 (fr) | Methode de traitement de maladies s'accompagnant d'alterations de la composition qualitative ou quantitative de l'adn extracellulaire du sang | |
WO2003055517A1 (fr) | Procede de correction de la reponse immunitaire et medicament | |
RU2500427C2 (ru) | Лекарственное средство для лечения функциональных нарушений желудочно-кишечного тракта и способ лечения функциональных нарушений желудочно-кишечного тракта | |
JPH03291236A (ja) | 感作t細胞関与疾患の治療剤 | |
CN107106672A (zh) | 用于预防和治疗免疫介导性疾病的针对胞壁酰肽的单克隆抗体 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 166270 Country of ref document: IL |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: JP |